David Beckham’s Supplement Brand Is Doing $10 Million A Month. The Secret Goes Beyond Just Celebrity.

Why It Matters

IM8 proves that scientific credibility can turn celebrity‑backed supplements into a scalable, high‑margin business, reshaping consumer expectations in a crowded wellness market.

Key Takeaways

• IM8 generated $120 M ARR and $10 M monthly revenue in year one
• Danny Yeung built a scientific advisory board to ensure product efficacy
• Clinical trials and third‑party testing set IM8 apart from competitors
• Direct‑to‑consumer strategy drives higher margins and brand control
• Longevity supplement line targets 14.3% market growth in 2025

Pulse Analysis

The supplement industry has long been plagued by celebrity hype and questionable efficacy, leaving consumers wary of unregulated products. David Beckham’s entry with IM8 could have been another flash‑in‑the‑pan endorsement, but the partnership with Danny Yeung—who previously grew Prenetics to $800 million in revenue—introduced a science‑first philosophy. By anchoring the brand in rigorous clinical trials, a distinguished advisory board, and transparent third‑party testing, IM8 addresses the trust deficit that has limited long‑term growth for many athlete‑backed lines.

Yeung’s strategy leverages his experience scaling data‑driven health ventures, applying the same metrics to supplement development. The advisory board includes leaders from the Mayo Clinic, Cedars‑Sinai, and even a former NASA chief scientist, providing credibility that resonates with both elite athletes and health‑conscious consumers. This scientific rigor, combined with a $100 price point, allows IM8 to command a premium while educating shoppers online about the tangible benefits of each ingredient—an approach far more sustainable than shelf‑space advertising.

From a business perspective, IM8’s direct‑to‑consumer model eliminates middlemen, boosting margins and enabling rapid feedback loops for product iteration. The brand’s $10 million monthly revenue and projected $180‑$200 million annual sales demonstrate the scalability of a trust‑centric model in a market growing at just 5.6% overall but 14.3% in longevity supplements. As consumers increasingly demand evidence‑based wellness solutions, IM8’s blend of celebrity reach and scientific validation could set a new benchmark for the industry.